Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative
The present disclosure relates to a compound of formula (1) as an anhydrate which is in a crystalline Form 2, characterized by having a powder-X-ray diffractogram displaying peaks expressed as degree 2-Theta angles at about 9.5; 11.8; 14.1; 14.6; 17.7 and 18.5 and a solid form thereof. The present disclosure also relates to processes for its preparation, as well as a medicament and a pharmaceutical composition comprising it. The present disclosure further concerns the anhydrate crystalline Form 2 of compound of formula (1) for use as a medicine and more particularly in the treatment of cancer.
1 . An anhydrate crystalline form, which is Form 2 of compound of formula (1)
characterized by having a powder-X-ray diffractogram displaying peaks expressed as degree 2-Theta angles at about 9.5; 11.8; 14.1; 14.6; 17.7 and 18.5.
2 . The anhydrate crystalline Form 2 of compound of formula (1) according to claim 1 , which further shows the following peaks expressed as degree 2-Theta angles: at about 15.5; 15.9; 16.6 and 22.2.
3 . The anhydrate crystalline Form 2 of compound of formula (1) according to claim 2 , wherein a differential scanning calorimetry (DSC) shows a melting endotherm at about 204° C. onset.
4 . The anhydrate crystalline Form 2 of compound of formula (1) according to claim 3 , characterized by showing a weight gain of less than 0.2 weight % based on the weight of the crystalline Form 2 anhydrate, as determined by Dynamic Vapor Sorption (DVS) in the range of from 0% to 95% relative humidity at a temperature of about 25° C.
5 . A process for the preparation of the anhydrate crystalline Form 2 of compound of formula (1) according to claim 1 , comprising at least the following steps:
1) solubilizing the compound of formula (1) in amorphous form in a solvent selected from alcohols, ketones, acetates, ethers and acetonitrile, optionally in admixture with water, at a set temperature ranging from 18° C. to 80° C.;
2) leaving the solution obtained in step 1) at the same temperature as the one set in step 1) for almost complete evaporation; and
3) isolating the anhydrate crystalline Form 2 of compound of formula (1) formed in step 2).
6 . The process according to claim 5 , wherein the solvent is selected from methanol, methanol/water mixture, ethanol, ethanol/water mixture, 2-propanol, 1-propanol, 1-propanol/water mixture, 1-butanol, 1-butanol/water mixture, acetone, acetone/water mixture, 2-butanone, 2-butanone/water mixture, methyl isobutyl ketone, methyl isobutyl ketone/water mixture, methyl acetate, methyl acetate/water mixture, ethyl acetate, ethyl acetate/water mixture, isopropyl acetate, isopropyl acetate/water mixture, isobutyl acetate, isobutyl acetate/water mixture, acetonitrile, and methyl tert-butyl ether.
7 . The process according to claim 5 , wherein the set temperature of step 1) and step 2) is selected from a range of temperature from 20° C. to 80° C.
8 . A process for the preparation of the anhydrate crystalline Form 2 of compound of formula (1) according to claim 1 , comprising at least the following steps:
1) solubilizing or suspending the compound of formula (1) in amorphous form in a solvent selected from alcohols, ketones, acetates, ethers and acetonitrile, at room temperature;
2) optionally purifying the solution or suspension obtained in step 1) by heating at a set temperature ranging from 60° C. to 80° C., stirring and filtering the solution or suspension;
3) heating the solution or suspension obtained in step 1) or in step 2) at a set temperature ranging from 60° C. to 80° C.;
4) cooling the solution or suspension obtained in step 2) to a set temperature ranging from −20° C. to 25° C.; and
5) isolating the anhydrate crystalline Form 2 of compound of formula (1) formed in step 4).
9 . The process according to claim 8 , wherein the solvent is selected from ethanol, 2-propanol, 1-propanol, 1-butanol, acetone, 2-butanone, methyl isobutyl ketone, isopentyl methyl ketone, methyl acetate, ethyl acetate, isopropyl acetate, isobutyl acetate, acetonitrile, and methyl tert-butyl ether.
10 . A process for the preparation of the anhydrate crystalline Form 2 of compound of formula (1) according to claim 1 , comprising at least the following steps:
1) solubilizing or suspending the compound of formula (1) in amorphous form in a solvent selected from alcohols, ketones, acetates, and diethyl-ether, at room temperature;
2) optionally filtering the solution or suspension obtained in step 1);
3) adding water as a non-solvent; and
4) isolating the anhydrate crystalline Form 2 of compound of formula (1) formed in step 3).
11 . The process according to claim 10 , wherein the solvent is selected from 2-propanol, 1-propanol, 1-butanol, acetone, 2-butanone, methyl isobutyl ketone, isopentyl methyl ketone, methyl acetate, ethyl acetate, isopropyl acetate, isobutyl acetate, and diethyl ether.
12 . A process for the preparation of the anhydrate crystalline Form 2 of compound of formula (1) according to claim 1 , comprising at least the following steps:
1) solubilizing or suspending the compound of formula (1) in amorphous form in a solvent selected from alcohols, ketones, and acetates, at a set temperature which is room temperature;
2) optionally filtering the solution or suspension obtained in step 1);
3) adding heptane as a non-solvent; and
4) isolating the anhydrate crystalline Form 2 of compound of formula (1) formed in step 3).
13 . The process according to claim 12 , wherein the solvent is selected from ethanol, 2-propanol, 1-propanol, 1-butanol, acetone, 2-butanone, methyl isobutyl ketone, isopentyl methyl ketone, methyl acetate, ethyl acetate, isopropyl acetate, and isobutyl acetate.
14 . A process for the preparation of the anhydrate crystalline Form 2 of compound of formula (1) according to claim 1 , comprising at least the following steps:
1) solubilizing or suspending the compound of formula (1) in amorphous form in an organic solvent; and
2) adding seeds of anhydrate crystalline Form 2 of the compound of formula (1).
15 . The process according to claim 14 , wherein steps 1) and 2) are followed by the step of adding a non-solvent, then performing distillation, followed by cooling and drying.
16 . A medicament, characterized in that it comprises the anhydrate crystalline Form 2 of compound of formula (1) according to claim 1 .
17 . A pharmaceutical composition comprising the anhydrate crystalline Form 2 of compound of formula (1) according to claim 1 , and at least one pharmaceutically acceptable excipient.
18 . The pharmaceutical composition according to claim 17 , wherein said anhydrate crystalline Form 2 is substantially pure and substantially free of alternative forms.
19 . The pharmaceutical composition according to claim 17 , wherein said anhydrate crystalline Form 2 is at least 90 percent by weight of all forms.
20 . A method of treating cancer comprising administering to a subject in need thereof a pharmaceutically effective amount of anhydrate crystalline Form 2 of compound of formula (1) according to claim 1 .
21 . The process according to claim 5 , wherein the set temperature of step 1) and step 2) is selected from a range of temperature from 25° C. to 80° C.